Active Stocks
Thu Mar 28 2024 15:59:33
  1. Tata Steel share price
  2. 155.90 2.00%
  1. ICICI Bank share price
  2. 1,095.75 1.08%
  1. HDFC Bank share price
  2. 1,448.20 0.52%
  1. ITC share price
  2. 428.55 0.13%
  1. Power Grid Corporation Of India share price
  2. 277.05 2.21%
Business News/ Companies / AstraZeneca leaves door ajar to Pfizer, despite hurdles
BackBack

AstraZeneca leaves door ajar to Pfizer, despite hurdles

CEO Pascal Soriot says his company has a bright future as a stand-alone firm but will negotiate if terms were attractive

AstraZeneca’s chief executive Pascal Soriot said he will engage with Pfizer if risks posed from forcing its operations into the US company’s new three-unit model were addressed. Photo: AFP Premium
AstraZeneca’s chief executive Pascal Soriot said he will engage with Pfizer if risks posed from forcing its operations into the US company’s new three-unit model were addressed. Photo: AFP

London: AstraZeneca Plc chief executive Pascal Soriot said on Wednesday that he would engage with Pfizer Inc. if the price was right and the risks posed from forcing the British drug maker’s operations into the US company’s new three-unit model were addressed.

Chief executive Pascal Soriot stressed his company had a bright future as a stand-alone firm but acknowledged that shareholders would expect AstraZeneca’s board to negotiate if terms were sufficiently attractive in a sweetened offer.

“Every shareholder says at the right level with the right offer you should consider it-that is very clear. But there is nobody who has told us a specific price at which we should engage," he told Reuters in an interview.

“If the offer was reflecting the value of the company but also addressing some of the integration aspects, the operating model and execution risks we are concerned about, then we certainly should engage—there’s no doubt."

Soriot and his team have held talks with the group’s leading investors during a round of meetings in London, Sweden and the US over the past week.

Pfizer made a cash-and-stock takeover approach on 2 May worth £50 a share to create the world’s largest drugs company, valuing AstraZeneca at $106 billion. The bid was promptly dismissed by the British group’s board—a decision that Soriot said had the firm backing of investors.

“There is no single shareholder who has told me or our CFO (chief financial officer) or our chairman that we should have accepted the offer," he said.

Buoyed by progress with its new drug pipeline—including a lung cancer medicine called AZD9291 for which data was released late on Wednesday—Soriot believes AstraZeneca can enjoy a strong independent future, but he has left the door ajar to a compelling offer.

In addition to price and the share of cash in any increased offer, Soriot said AstraZeneca would also need assurances about the risks faced by Pfizer in implementing a complex merger and integrating operations across two sprawling organisations.

In particular, he highlighted the problems posed by the fact that Pfizer is now separating its operations into three business units—a structure that would clash with AstraZeneca, where the MedImmune biotech unit, for example, serves all parts of the group.

Pfizer provided detailed financial results for its three business units for the first time last week, when it reported first-quarter results, as a prelude to possibly divesting one or more of them in 2017.

Soriot is also worried about diluting the focus on science in the new group and the risk to reputation in Pfizer’s controversial plan to re-domicile in Britain in order to minimise its tax payments.

“All those issues will need to be discussed, but step one is to get to an offer that reflects the value of the company," Soriot said.

He was speaking after being questioned for two days by British politicians who are concerned about the impact of a Pfizer takeover on British science jobs.

Cancer drug hopes

Soriot stressed there was “no inevitability" to a deal with Pfizer, since AstraZeneca’s improving pipeline of new drugs was transforming its prospects, following a lean period in its research labs and a wave of patent expiries.

AstraZeneca predicted last week that its sales would increase by 75% to more than $45 billion a year by 2023.

Much of the hope for the pipeline hinges on the company’s suite of experimental cancer drugs, further details of which are due at the annual American Society of Clinical Oncology (ASCO) conference on 30 May-3 June.

One of those drugs, lung cancer treatment AZD9291, has produced promising results in an early-stage clinical trial, details of which were released ahead of the ASCO meeting. The drug, which shrank tumours in more than half of patients, is a potential replacement for established lung cancer pills Tarceva and Iressa.

Soriot also highlighted the potential of MEDI4736, a medicine designed to boost the immune system, and a promising combination of two other cancer drugs, olaparib and cediranib.

“We think we can succeed because we have innovative products, not because we have a large commercial offering," Soriot said.

“At ASCO, we will show phase I (clinical trial) results but also share some information about our development plans, which will show people where we think we can be first and where we think we can potentially come up with treatment algorithms that will totally change the way some types of cancer are treated." Reuters

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

Catch all the Corporate news and Updates on Live Mint. Download The Mint News App to get Daily Market Updates & Live Business News.
More Less
Published: 15 May 2014, 10:25 AM IST
Next Story footLogo
Recommended For You
Switch to the Mint app for fast and personalized news - Get App